Toth Financial Advisory Corp Sells 22,666 Shares of Medtronic PLC $MDT

Toth Financial Advisory Corp cut its holdings in Medtronic PLC (NYSE:MDT) by 28.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 56,404 shares of the medical technology company’s stock after selling 22,666 shares during the period. Toth Financial Advisory Corp’s holdings in Medtronic were worth $4,412,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of MDT. Monetary Solutions Ltd purchased a new position in shares of Medtronic in the fourth quarter worth $27,000. Anfield Capital Management LLC increased its position in shares of Medtronic by 410.7% in the fourth quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock valued at $27,000 after acquiring an additional 230 shares during the period. Acumen Wealth Advisors LLC bought a new position in shares of Medtronic during the fourth quarter valued at about $29,000. Imprint Wealth LLC purchased a new stake in shares of Medtronic during the third quarter worth about $31,000. Finally, Basepoint Wealth LLC bought a new stake in shares of Medtronic in the fourth quarter worth about $32,000. Institutional investors own 82.06% of the company’s stock.

Medtronic Trading Up 1.5%

Shares of MDT stock opened at $91.28 on Friday. The firm has a fifty day moving average price of $85.57 and a 200-day moving average price of $85.67. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.13 and a quick ratio of 1.62. Medtronic PLC has a 1 year low of $73.31 and a 1 year high of $106.33. The company has a market cap of $116.84 billion, a price-to-earnings ratio of 24.47, a PEG ratio of 2.41 and a beta of 0.55.

Medtronic (NYSE:MDT) last posted its quarterly earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share for the quarter, topping analysts’ consensus estimates of $1.54 by $0.01. Medtronic had a net margin of 13.20% and a return on equity of 14.51%. The business had revenue of $9.81 billion during the quarter, compared to analyst estimates of $9.62 billion. During the same period in the prior year, the business posted $1.62 earnings per share. The company’s revenue was up 9.9% on a year-over-year basis. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. As a group, equities analysts predict that Medtronic PLC will post 5.94 earnings per share for the current year.

Medtronic Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 16th. Investors of record on Friday, September 25th will be given a $0.72 dividend. This represents a $2.88 annualized dividend and a yield of 3.2%. The ex-dividend date is Friday, September 25th. Medtronic’s payout ratio is currently 77.21%.

Medtronic News Roundup

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Needham raised its price target to $114 from $101 and reiterated a “Buy” rating, implying substantial upside from recent trading levels. The firm reportedly expects Medtronic to beat first-quarter estimates and raise its fiscal 2027 guidance. Needham raises Medtronic price target
• Positive Sentiment: Analysts see potential for Medtronic to exceed consensus first-quarter expectations of approximately $1.39 in adjusted EPS and $9.54 billion in revenue. A stronger-than-expected report could support the shares, particularly if management lifts its fiscal 2027 outlook. Medtronic earnings estimates
• Positive Sentiment: Recent coverage highlights momentum in Medtronic’s cardiovascular businesses and growth in renal denervation, while broader device demand is supporting the company’s rebound narrative. Medtronic device momentum
• Neutral Sentiment: The imminent earnings release is likely to keep volatility elevated. Investors will evaluate quarterly performance, procedure trends, and management’s fiscal 2027 guidance for confirmation that the recovery is sustainable. Medtronic rebound outlook
• Negative Sentiment: Tariff exposure and unfavorable currency movements remain potential headwinds to margins and reported growth. These risks could limit the benefit of strong cardiovascular trends or weigh on the shares if management issues cautious guidance. Medtronic portfolio outlook

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on MDT shares. Needham & Company LLC increased their price objective on Medtronic from $101.00 to $114.00 and gave the stock a “buy” rating in a report on Thursday. Piper Sandler reiterated a “neutral” rating on shares of Medtronic in a research note on Monday, August 10th. Evercore set a $105.00 price target on shares of Medtronic in a research report on Monday, July 6th. Weiss Ratings reissued a “hold (c)” rating on shares of Medtronic in a research note on Tuesday, August 18th. Finally, TD Cowen upped their price objective on shares of Medtronic from $100.00 to $110.00 and gave the stock a “buy” rating in a report on Friday. Eighteen equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $99.79.

Insider Buying and Selling

In related news, EVP Harry Skip Kiil sold 4,189 shares of Medtronic stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $80.44, for a total value of $336,963.16. Following the completion of the transaction, the executive vice president owned 37,227 shares in the company, valued at approximately $2,994,539.88. This trade represents a 10.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.27% of the company’s stock.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter?defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).